Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

doi:10.1016/j.ejca.2024.115161

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2025

Dimitriou Florentia, Orloff Marlana M, Koch Hein Erica C, Cheng Phil F, Hughes Isaac F, Simeone Ester, Montazeri Kamaneh, Grover Piyush, Mehmi Inderjit, Gerard Camille L, Gaudy-Marqueste Caroline, Grob Jean-Jacques, Michielin Olivier, Hamid Omid, Long Georgina V, Sullivan Ryan, Kapiteijn Ellen, Johnson Douglas B, Ascierto Paolo A, Joshua Anthony M, Carvajal Richard D, Butler Marcus O, Hassel Jessica C, Dummer Reinhard

Abstract excerpt

BACKGROUND: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to investigate the efficacy and safety of the sequence of tebentafusp and ICIs. METHODS: Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to GTP-Binding Protein alpha Subunits

Share to GTP-Binding Protein alpha Subunits, Gq-G11

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Open in PubMed

Identifiers

PMID: 39647344
DOI: 10.1016/j.ejca.2024.115161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.PMID 39647344Read ↗

Uveal melanoma: epidemiology, etiology, and treatment of primary diseaseSemantic proximity Read ↗

Recent approaches for the treatment of uveal melanoma: Opportunities and challenges.Semantic proximity Read ↗

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read ↗

Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma.Semantic proximity Read ↗

Development of a Metastatic Uveal Melanoma Prognostic risk Score (MUMPS) for use in patients receiving immune checkpoint inhibitorsSemantic proximity Read ↗

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patientsSemantic proximity Read ↗

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal MelanomaSemantic proximity Read ↗

Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?Semantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.Semantic proximity Read ↗

Continuous Infusion of Endostar Combined with Chemotherapy in Patients with Advanced or Recurrent Mucosal Melanoma: A Real-World Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.